Literature DB >> 15853926

Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts.

Sotiria Boukouvala1, Edith Sim.   

Abstract

Arylamine N-acetyltransferases are polymorphic drug-metabolising enzymes. The human isoforms, NAT1 and NAT2, are encoded by two genes with intronless coding regions. Human NAT1 protein is found in many tissues, unlike NAT2 which is present predominantly in the intestine and liver. We describe the exon-intron structure of the human NAT genes by analysing data from genomic databases. Comparison of expressed sequence tags, matching NAT gene sequences, with the sequence of human chromosome 8 implied the presence of 8 non-coding exons located 51.5, 51.4, 12.3, 11.9, 10.8, 9.6, 5.2 and 2.6 kb upstream of the single coding exon of the NAT1 gene. A number of expressed sequence tags also indicated transcription initiation from the upstream region adjacent to the NAT1 coding exon, consistent with earlier studies. The NAT2 gene consists of one previously described non-coding and one coding exon, located 8.6 kb apart. These findings were also confirmed by RT-PCR, using cDNA from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Alternatively spliced NAT1 transcripts were found in all tissues. Transcription of the NAT2 gene was also detected in these tissues and was demonstrated to start either from the non-coding exon or from immediately upstream of the coding exon. Comparison of the RT-PCR products provided an initial estimate of the relative amounts of the different NAT transcripts expressed in each tissue. Finally, both expressed sequence tag analysis and RT-PCR demonstrated the presence of two differentially utilised polyadenylation signals for NAT1 and NAT2, located about 0.2 and 0.3 kb downstream of the coding region of each gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15853926     DOI: 10.1111/j.1742-7843.2005.pto_02.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  25 in total

Review 1.  mRNA transcript diversity creates new opportunities for pharmacological intervention.

Authors:  Elizabeth S Barrie; Ryan M Smith; Jonathan C Sanford; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2012-02-07       Impact factor: 4.436

2.  NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenyl.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Mol Carcinog       Date:  2011-08-11       Impact factor: 4.784

3.  Glucocorticoid receptor-mediated transcriptional regulation of N-acetyltransferase 1 gene through distal promoter.

Authors:  Barbara Bonamassa; Yongjie Ma; Dexi Liu
Journal:  AAPS J       Date:  2012-05-30       Impact factor: 4.009

4.  Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1.

Authors:  David F Barker; Anwar Husain; Jason R Neale; Benjamin D Martini; Xiaoyan Zhang; Mark A Doll; J Christopher States; David W Hein
Journal:  Pharmacogenet Genomics       Date:  2006-07       Impact factor: 2.089

5.  N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice.

Authors:  Jennifer A Loehle; Valerie Cornish; Larissa Wakefield; Mark A Doll; Jason R Neale; Yu Zang; Edith Sim; David W Hein
Journal:  J Pharmacol Exp Ther       Date:  2006-07-20       Impact factor: 4.030

6.  Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity.

Authors:  Danxin Wang; Michael F Para; Susan L Koletar; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

7.  Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-02-07       Impact factor: 3.922

8.  Water-soluble mmp-9 inhibitor prodrug generates active metabolites that cross the blood-brain barrier.

Authors:  Wei Song; Zhihong Peng; Major Gooyit; Mark A Suckow; Valerie A Schroeder; William R Wolter; Mijoon Lee; Masajiro Ikejiri; Jiankun Cui; Zezong Gu; Mayland Chang
Journal:  ACS Chem Neurosci       Date:  2013-05-30       Impact factor: 4.418

9.  N-acetyltransferase 1 and 2 gene sequence variants and risk of head and neck cancer.

Authors:  Semra Demokan; Yusufhan Suoglu; Mustafa Gözeler; Deniz Demir; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2009-11-08       Impact factor: 2.316

Review 10.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.